Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

NCT03954704 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped The decision to discontinue the study was made based on the totality of the clinical, pharmacokinetic, and pharmacodynamic findings. No safety concerns were observed.

Conditions

Interventions

Sponsor

Gilead Sciences